# NCT03214250 (NCT03214250)

> Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03214250
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Parker Institute for Cancer Immunotherapy
- Conditions: Metastatic Pancreatic Adenocarcinoma
- Interventions: APX005M; Nivolumab; Nab-Paclitaxel; Gemcitabine
- Enrollment: 129
- Primary outcome: Phase 1b Primary Safety Outcome
- Primary outcome: 1-year Overall Survival Rate

## Indexed commentary on NCT03214250 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03214250